Showing results (1-10 of 592) with videos related to
Sort By:
Pageof 60
Cancer|October 26, 2007
Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphataseWanling Xie, Mari Nakabayashi, Meredith M Regan, et al.JNCI Cancer Spectrum|July 31, 2019
A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analysesWanling Xie, Susan Halabi, Jayne F Tierney, et al.Cancer Journal (Sudbury, Mass.)|May 4, 2007
Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancerMari Nakabayashi, Jonathan Ling, Wanling Xie, et al.Cancer|July 25, 2006
Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancerMari Nakabayashi, Wanling Xie, Meredith M Regan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2006
Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancerMary-Ellen Taplin, Wanling Xie, Glenn J Bubley, et al.Prostate Cancer and Prostatic Diseases|January 8, 2025
Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancerPraful Ravi, Wanling Xie, Silke Gillessen, et al.Breast (Edinburgh, Scotland)|December 17, 2019
Risk stratification according to stage and pathologyMeredith M ReganBreast (Edinburgh, Scotland)|August 10, 2015
Predicting benefit of endocrine therapy for early breast cancerMeredith M ReganBreast (Edinburgh, Scotland)|November 27, 2021
Accelerating progress to innovation for patients: Trial design and risk stratificationMeredith M ReganBJU International|March 18, 2011
Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapyDipika Misra, Wanling Xie, Meredith M Regan, et al.Pageof 60